Healthcare AI Governance Framework: What Certification Now Requires

The single most common gap is diffusion of responsibility. AI enters healthcare organizations through many doors at once, embedded in the EHR, bought by revenue cycle, piloted by a service line, trialled by an individual clinician, and no one owns the aggregate. Governance guidance is explicit that a formal structure with a designated individual holding appropriate technology or healthcare experience is expected. That person needs authority to say no, which means the structure has to sit high enough in the organization to survive a service line chief disagreeing with it.

AI governance failures often turn out to be data governance failures wearing a different label. A model performing poorly because it was trained on a population unlike yours, an inference call sending protected health information to a vendor without a business associate agreement, a fine-tuning dataset assembled from records whose consent basis nobody documented: each is a data problem surfaced by AI adoption. Governance frameworks therefore treat data provenance, protection, and vendor contracting as a domain in its own right rather than an implementation detail.

This domain is where vendor claims meet local reality. A model validated on a national dataset may perform materially differently on your population, and governance guidance is direct that organizations should ask vendors how validation was performed, whether local validation is possible, and how relevant biases were evaluated. The uncomfortable finding in many assessments is that these questions were never asked during procurement, which means the organization deployed a tool whose performance in its own setting is simply unknown.

Pre-deployment validation is a point-in-time result and models degrade. Populations shift, documentation practices change, upstream data pipelines are modified, and vendors update models under the hood. Governance guidance treats ongoing quality monitoring as risk-based and scaled to setting, with responsible parties identified locally and regular validation performed. It also emphasizes voluntary internal reporting of incidents and near-misses, on the reasoning that organizations with strong reporting culture surface problems while they are still small.

The final domain is the one technical teams consistently underweight. Governance guidance calls for a mechanism to disclose AI use, patient notification where AI directly affects care, education about how patient data may be used, and consent where relevant. It equally calls for workforce education so clinicians understand both capability and limitation. Both halves matter, because a disclosed tool used by untrained clinicians who over-trust its output produces the same patient harm as an undisclosed one.

Federal posture on AI regulation has been deregulatory, and the certification pathway is voluntary, which leads some organizations to conclude that nothing binding applies. That reading misses where the enforceable obligations are accumulating. ASTP/ONC’s HTI-1 rule introduced decision support intervention transparency requirements for certified health IT, and the HTI-5 proposal would remove them, meaning one of the few federal AI transparency guardrails may be withdrawn. Meanwhile states have continued legislating, and state law does not depend on federal rulemaking to apply to your deployment.

We work only in healthcare, and since 2013 we have delivered more than 500 software projects across over 200 organizations. Governance work sits between compliance and engineering, which is why it stalls in most organizations: compliance teams cannot specify the technical controls, and engineering teams cannot interpret the standards. We build the connecting layer, meaning the inventory system, the validation and monitoring infrastructure, the evidence pipeline, and the documentation that makes governance demonstrable rather than aspirational.